Stable Mammalian Serum Albumins Designed for Bacterial Expression.


Journal

Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 21 03 2023
revised: 18 06 2023
accepted: 20 06 2023
medline: 15 8 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

Albumin is the most abundant protein in the blood serum of mammals and has essential carrier and physiological roles. Albumins are also used in a wide variety of molecular and cellular experiments and in the cultivated meat industry. Despite their importance, however, albumins are challenging for heterologous expression in microbial hosts, likely due to 17 conserved intramolecular disulfide bonds. Therefore, albumins used in research and biotechnological applications either derive from animal serum, despite severe ethical and reproducibility concerns, or from recombinant expression in yeast or rice. We use the PROSS algorithm to stabilize human and bovine serum albumins, finding that all are highly expressed in E. coli. Design accuracy is verified by crystallographic analysis of a human albumin variant with 16 mutations. This albumin variant exhibits ligand binding properties similar to those of the wild type. Remarkably, a design with 73 mutations relative to human albumin exhibits over 40 °C improved stability and is stable beyond the boiling point of water. Our results suggest that proteins with many disulfide bridges have the potential to exhibit extreme stability when subjected to design. The designed albumins may be used to make economical, reproducible, and animal-free reagents for molecular and cell biology. They also open the way to high-throughput screening to study and enhance albumin carrier properties.

Identifiants

pubmed: 37385581
pii: S0022-2836(23)00290-5
doi: 10.1016/j.jmb.2023.168191
pii:
doi:

Substances chimiques

Disulfides 0
Serum Albumin 0
Serum Albumin, Human ZIF514RVZR
Recombinant Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

168191

Subventions

Organisme : European Research Council
ID : 815379
Pays : International

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: O.K. and S.J.F. are named inventors in a patent application filed by Weizmann Institute of Science on the stabilized albumin variants. SJF is a paid consultant to companies that apply protein design algorithms.

Auteurs

Olga Khersonsky (O)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: olga.khersonsky@weizmann.ac.il.

Moshe Goldsmith (M)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.

Irina Zaretsky (I)

Antibody Engineering Unit, Weizmann Institute of Science, Rehovot 7610001, Israel.

Shelly Hamer-Rogotner (S)

Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot 7610001, Israel.

Orly Dym (O)

Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot 7610001, Israel.

Tamar Unger (T)

Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot 7610001, Israel.

Meital Yona (M)

Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot 7610001, Israel.

Yael Fridmann-Sirkis (Y)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.

Sarel J Fleishman (SJ)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: sarel.fleishman@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH